中金：优化药品集中采购 “双目录”机制进一步推进支付改革

Group 1 - The core viewpoint of the article highlights that the Central Economic Work Conference proposed policies to optimize drug procurement and deepen medical insurance payment reforms, which are expected to boost domestic demand in the pharmaceutical industry and signal a shift towards high-quality development for Chinese pharmaceutical companies [1] - The optimization of drug centralized procurement is aligned with the principle of "anti-involution," aiming to stabilize production and achieve a sustainable balance between affordable pricing and reliable quality in clinical medications [1] - The introduction of a "dual directory" mechanism for medical insurance payment reform is expected to facilitate the inclusion of high-value innovative drugs that are not covered by basic medical insurance, thus supporting innovation while ensuring basic healthcare needs are met [2] Group 2 - The establishment of a national long-term care insurance service project directory is anticipated to standardize long-term care services, enhance service quality, and stabilize the rights of beneficiaries, contributing to the smooth operation of long-term care insurance funds [3]